Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
-
- STATUS
- Recruiting
-
- End date
- Dec 21, 2032
-
- participants needed
- 600
-
- sponsor
- Hospital de Clinicas de Porto Alegre
Summary
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
Description
Methylphenidate (MPH) is the most prescribed psychostimulant for children and adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Meta-analyses and systematic reviews have shown that MPH is safe and efficacious in attenuating the core symptoms of ADHD, promoting overall clinical improvement. However, many patients still do not show an appropriate clinical response to the MPH treatment and there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. Therefore, it is essential to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
Details
| Condition | Oppositional Defiant Disorder, Oppositional Defiant Disorder (ODD), Attention deficit hyperactivity disorder, Attention Deficit/Hyperactivity Disorder (ADHD - Pediatric), Attention Deficit/Hyperactivity Disorder (ADHD - Adults), Family Medicine-ADHD Pediatrics, Attention Deficit/Hyperactivity Disorder (ADHD - Adults), Attention Deficit/Hyperactivity Disorder (ADHD - Pediatric), Oppositional Defiant Disorder (ODD), Family Medicine-ADHD Pediatrics, adhd |
|---|---|
| Treatment | Immediate-release Methylphenidate |
| Clinical Study Identifier | NCT02951754 |
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Last Modified on | 21 January 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer